Dihydroergotamine - NDSRI's
References
FAQ's
References
- Stoll, Arthur; Hofmann, Albert, Methane Sulfonic Acid Salt Of Di-Hydro-Ergotamine, Sandoz Ltd., US2507830A, May 16, 1980
- Niazy, Esmail M.; Molokhia, Abdulla M.; El-Gorashi, Abubakr S., Quick and simple determination of dihydroergotamine by high-performance liquid chromatography, Analytical Letters, Volume: 21, Issue: 10, Pages: 1833-43, 1988
Frequently Asked Questions
How often are Dihydroergotamine impurities monitored post-manufacturing?
Dihydroergotamine impurities are regularly monitored post-manufacturing to assess the stability and quality of the drug product over its shelf life. Monitoring frequency may vary depending on regulatory requirements and the specific formulation of the drug.
What measures help to minimize the formation of Dihydroergotamine impurities?
To minimize the formation of Dihydroergotamine impurities, manufacturers can ensure the use of high-quality starting materials, optimize reaction conditions, implement effective purification techniques, and maintain proper storage and handling conditions.
Can Dihydroergotamine impurities be eliminated?
It may not be possible to eliminate impurities. Their levels can be controlled and minimized through optimized manufacturing processes, appropriate storage conditions, and strict quality control measures.
What are the temperature conditions required to store Dihydroergotamine impurities?
Dihydroergotamine impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.